Merck opens generic production of new HIV prevention pill at $5 a year

Wo das Thema steht

Merck has moved its new HIV prevention pill from promise to production: the company has licensed manufacturers in Africa and India to make generic versions, at a price that could fall to roughly $5 per person per year, according to the New York Times. The arrangement is aimed at the regions carrying the heaviest HIV burden, and it marks the point at which a drug previously discussed in terms of its potential becomes tied to a concrete manufacturing footprint on two continents and a stated per-person cost. What the licensing does not yet settle is where else the pill will reach. Access across much of Latin America remains uncertain on the same account, leaving a gap between the supply arrangements now in place and the wider question of who will be able to obtain the drug. The topic now stands at that divide: manufacturing and pricing established for the highest-burden regions, distribution beyond them still open.

HIV prevention in pill form, taken by people who are not infected to keep them from acquiring the virus, has long been constrained less by science than by cost and supply. Merck has developed a new prevention pill, and the central question around it has been whether it would be priced and produced in a way that reaches the countries where HIV is most prevalent. Licensing generic manufacturing to other companies is the mechanism by which a patented drug can be made at low cost in and for those countries. The reported figure of about $5 per person per year, and the choice of manufacturers in Africa and India, are the terms of that arrangement as described by the New York Times. Whether comparable access follows in other regions, including much of Latin America, is not yet established.